ARAY
Price
$1.52
Change
-$0.07 (-4.40%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
244.95M
70 days until earnings call
ZOMDF
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Jun 4 closing price
Capitalization
137.19M
Interact to see
Advertisement

ARAY vs ZOMDF

Header iconARAY vs ZOMDF Comparison
Open Charts ARAY vs ZOMDFBanner chart's image
Accuray
Price$1.52
Change-$0.07 (-4.40%)
Volume$6.17K
Capitalization244.95M
Zomedica
Price$0.04
Change-$0.00 (-0.00%)
Volume$869.17K
Capitalization137.19M
ARAY vs ZOMDF Comparison Chart
Loading...
ARAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZOMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARAY vs. ZOMDF commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARAY is a Buy and ZOMDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ARAY: $1.52 vs. ZOMDF: $0.05)
Brand notoriety: ARAY and ZOMDF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ARAY: 63% vs. ZOMDF: 39%
Market capitalization -- ARAY: $244.95M vs. ZOMDF: $137.19M
ARAY [@Medical Specialties] is valued at $244.95M. ZOMDF’s [@Medical Specialties] market capitalization is $137.19M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARAY’s FA Score shows that 0 FA rating(s) are green whileZOMDF’s FA Score has 1 green FA rating(s).

  • ARAY’s FA Score: 0 green, 5 red.
  • ZOMDF’s FA Score: 1 green, 4 red.
According to our system of comparison, ARAY is a better buy in the long-term than ZOMDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARAY’s TA Score shows that 7 TA indicator(s) are bullish while ZOMDF’s TA Score has 4 bullish TA indicator(s).

  • ARAY’s TA Score: 7 bullish, 3 bearish.
  • ZOMDF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ARAY is a better buy in the short-term than ZOMDF.

Price Growth

ARAY (@Medical Specialties) experienced а -3.48% price change this week, while ZOMDF (@Medical Specialties) price change was +0.35% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.32%. For the same industry, the average monthly price growth was +4.56%, and the average quarterly price growth was +1.00%.

Reported Earning Dates

ARAY is expected to report earnings on Aug 14, 2025.

Industries' Descriptions

@Medical Specialties (+0.32% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARAY($245M) has a higher market cap than ZOMDF($137M). ARAY YTD gains are higher at: -19.697 vs. ZOMDF (-63.333). ARAY has higher annual earnings (EBITDA): 5.93M vs. ZOMDF (-11.94M). ZOMDF has more cash in the bank: 106M vs. ARAY (72.8M). ZOMDF has less debt than ARAY: ZOMDF (1.75M) vs ARAY (202M). ARAY has higher revenues than ZOMDF: ARAY (447M) vs ZOMDF (24M).
ARAYZOMDFARAY / ZOMDF
Capitalization245M137M179%
EBITDA5.93M-11.94M-50%
Gain YTD-19.697-63.33331%
P/E RatioN/AN/A-
Revenue447M24M1,863%
Total Cash72.8M106M69%
Total Debt202M1.75M11,530%
FUNDAMENTALS RATINGS
ARAY vs ZOMDF: Fundamental Ratings
ARAY
ZOMDF
OUTLOOK RATING
1..100
7379
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8892
PRICE GROWTH RATING
1..100
5892
P/E GROWTH RATING
1..100
46100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZOMDF's Valuation (26) in the Pharmaceuticals Major industry is somewhat better than the same rating for ARAY (86) in the Medical Specialties industry. This means that ZOMDF’s stock grew somewhat faster than ARAY’s over the last 12 months.

ZOMDF's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ARAY (100) in the Medical Specialties industry. This means that ZOMDF’s stock grew similarly to ARAY’s over the last 12 months.

ARAY's SMR Rating (88) in the Medical Specialties industry is in the same range as ZOMDF (92) in the Pharmaceuticals Major industry. This means that ARAY’s stock grew similarly to ZOMDF’s over the last 12 months.

ARAY's Price Growth Rating (58) in the Medical Specialties industry is somewhat better than the same rating for ZOMDF (92) in the Pharmaceuticals Major industry. This means that ARAY’s stock grew somewhat faster than ZOMDF’s over the last 12 months.

ARAY's P/E Growth Rating (46) in the Medical Specialties industry is somewhat better than the same rating for ZOMDF (100) in the Pharmaceuticals Major industry. This means that ARAY’s stock grew somewhat faster than ZOMDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARAYZOMDF
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 15 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
79%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ARAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZOMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGOAX58.66N/A
N/A
Hartford Growth Opportunities A
JIVAX30.07N/A
N/A
JPMorgan U.S. Applied Data Sci Val A
LMORX36.02N/A
N/A
Patient Opportunity R
PRPCX4.94N/A
N/A
PGIM Jennison Energy Infrastructure C
PAHSX6.95N/A
N/A
PGIM Jennison NextGeneration Glb Opps A

ARAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARAY has been loosely correlated with ALGN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAY jumps, then ALGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARAY
1D Price
Change %
ARAY100%
+1.27%
ALGN - ARAY
46%
Loosely correlated
+0.46%
IQV - ARAY
44%
Loosely correlated
+3.59%
NVST - ARAY
43%
Loosely correlated
+0.11%
KIDS - ARAY
42%
Loosely correlated
-1.57%
ILMN - ARAY
42%
Loosely correlated
+1.63%
More

ZOMDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZOMDF has been loosely correlated with SNDL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ZOMDF jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZOMDF
1D Price
Change %
ZOMDF100%
N/A
SNDL - ZOMDF
38%
Loosely correlated
+0.78%
CDNA - ZOMDF
30%
Poorly correlated
+10.67%
EBS - ZOMDF
29%
Poorly correlated
-1.25%
ARAY - ZOMDF
29%
Poorly correlated
+1.27%
BNR - ZOMDF
28%
Poorly correlated
-2.68%
More